Insulet Corp (PODD):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Insulet Corp (PODD) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7458
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. Its OmniPod insulin management system is a continuous insulin delivery system for insulin dependent diabetic s. Omnipod system consists of a disposable self-adhesive tubeless insulin infusion device, OmniPod, and a handheld wireless device, Personal Diabetes Manager. The company also works in partnership with biotechnology and pharmaceutical companies that utilize the customized form of its Omnipod system to deliver drugs at specified intervals of time at predetermined doses. The company markets and sells its products directly and through distribution partners in North America, Asia and Europe. Insulet is headquartered in Billerica, Massachusetts, the US.

Insulet Corp (PODD) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Insulet Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Insulet Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Insulet Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Insulet Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Insulet Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Insulet Corp, Medical Equipment, Deal Details 11
Asset Purchase 11
Insulet Acquires US Manufacturing Facility in Acton, Massachusetts 11
Venture Financing 12
Glooko Raises USD35 Million in Series C Financing 12
Partnerships 14
Insulet Enters into Licensing Agreement with Mode AGC 14
Insulet Extends Licensing Agreement with Abbott Diabetes Care 15
Insulet Amends Licensing Agreement With Abbott Diabetes 16
Ascensia Diabetes Care Expands Agreement with Insulet 17
Insulet Enters into Co-Development Agreement with Eli Lilly 18
Insulet Enters Into Co-Development Agreement With Eli Lilly 19
Insulet Expands Distribution Agreement With Ypsomed Holding 20
Insulet Enters Into Technology Integration Agreement With LifeScan 21
Equity Offering 22
Insulet Completes Public Offering Of Common Stock For US$98 Million 22
Debt Offering 24
Insulet Prices Private Placement of 1.375% Notes Due 2024 for USD350 Million 24
Insulet Raises Private Placement of Senior Notes for USD345 Million 25
Insulet Prices Public Offering of 2% Notes Due 2019 for USD175 Million 26
Acquisition 28
Liberty Medical Acquires Neighborhood Diabetes from Insulet for USD5 Million 28
Insulet Corp – Key Competitors 29
Insulet Corp – Key Employees 30
Insulet Corp – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Strategy And Business Planning 32
Sep 28, 2017: Insulet Breaks Ground on New U.S. Manufacturing Facility 32
Financial Announcements 33
Aug 02, 2018: Insulet Reports second quarter 2018 revenue of $124.3 million, up 13% year-over-year, and gross margin of 66%, up 710 basis points 33
May 03, 2018: Insulet Reports First Quarter 2018 Financial Results 34
Feb 21, 2018: Insulet Reports Fourth Quarter Revenue of $130.5 Million In Fourth Quarter Of 2017 36
Nov 02, 2017: Insulet Reports Third Quarter 2017 Financial Results 38
Aug 03, 2017: Insulet Reports Second Quarter 2017 Financial Results 39
May 08, 2017: Insulet Reports First Quarter 2017 Financial Results 40
Feb 27, 2017: Insulet Reports Fourth Quarter and Full Year 2016 Financial Results 41
Corporate Communications 43
Sep 10, 2018: Insulet announces Shacey Petrovic, President and COO, promoted to CEO, effective January 1, 2019; Patrick Sullivan will retire as Chairman and CEO at the end of 2018 43
Aug 10, 2017: Insulet Appoints Michael R. Minogue and James C. Mullen to Board of Directors 45
May 30, 2017: Insulet Appoints Bret Christensen as Chief Commercial Officer 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Insulet Corp, Medical Equipment, Key Facts, 2017 2
Insulet Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Insulet Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Insulet Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Insulet Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Insulet Corp, Deals By Market, 2012 to YTD 2018 9
Insulet Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Insulet Acquires US Manufacturing Facility in Acton, Massachusetts 11
Glooko Raises USD35 Million in Series C Financing 12
Insulet Enters into Licensing Agreement with Mode AGC 14
Insulet Extends Licensing Agreement with Abbott Diabetes Care 15
Insulet Amends Licensing Agreement With Abbott Diabetes 16
Ascensia Diabetes Care Expands Agreement with Insulet 17
Insulet Enters into Co-Development Agreement with Eli Lilly 18
Insulet Enters Into Co-Development Agreement With Eli Lilly 19
Insulet Expands Distribution Agreement With Ypsomed Holding 20
Insulet Enters Into Technology Integration Agreement With LifeScan 21
Insulet Completes Public Offering Of Common Stock For US$98 Million 22
Insulet Prices Private Placement of 1.375% Notes Due 2024 for USD350 Million 24
Insulet Raises Private Placement of Senior Notes for USD345 Million 25
Insulet Prices Public Offering of 2% Notes Due 2019 for USD175 Million 26
Liberty Medical Acquires Neighborhood Diabetes from Insulet for USD5 Million 28
Insulet Corp, Key Competitors 29
Insulet Corp, Key Employees 30
Insulet Corp, Other Locations 31
Insulet Corp, Subsidiaries 31

List of Figures
Insulet Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Insulet Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Insulet Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Insulet Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Insulet Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Insulet Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Insulet Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Insulet Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Insulet Corp (PODD):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DPR Construction Inc:企業の戦略的SWOT分析
    DPR Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Graham Holdings Company:企業の戦略・SWOT・財務情報
    Graham Holdings Company - Strategy, SWOT and Corporate Finance Report Summary Graham Holdings Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Protective Life Corporation:企業の戦略・SWOT・財務情報
    Protective Life Corporation - Strategy, SWOT and Corporate Finance Report Summary Protective Life Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Laricina Energy Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Laricina Energy Ltd (Laricina Energy) is an upstream oil and gas company that explores, produces and develops oil sand properties in Western Canada. The company offers development of underground bitumen deposits in sand and carbonate formations. It operates Germain property and Saleski prope …
  • Sequella Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. S …
  • SoftBank Group Corporation:企業のM&A・事業提携・投資動向
    SoftBank Group Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SoftBank Group Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • The National Gas Company of Trinidad and Tobago Ltd:企業の戦略的SWOT分析
    The National Gas Company of Trinidad and Tobago Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Cobra Electronics Corporation:企業の戦略的SWOT分析
    Cobra Electronics Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Nishimatsu Construction Co Ltd (1820):企業の財務・戦略的SWOT分析
    Nishimatsu Construction Co Ltd (1820) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Prognomix Inc:企業の製品パイプライン分析
    Summary Prognomix Inc (Prognomix) is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company’s products include PGX IR01, PGx GR01, PGx CD01, PGx IR02 …
  • PDL BioPharma Inc (PDLI):製薬・医療:M&Aディール及び事業提携情報
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Enerkem Inc:企業の戦略的SWOT分析
    Enerkem Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Addex Therapeutics Ltd (ADXN):製薬・医療:M&Aディール及び事業提携情報
    Summary Addex Therapeutics Ltd (Addex) develops orally available, small molecule allosteric modulators for neurological disorders. The company’s product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator or NAM) to treat Parkinson’s disease levodopa-induced dy …
  • Vedanta Ltd:企業のM&A・事業提携・投資動向
    Vedanta Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vedanta Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Cellect Biotechnology Ltd (APOP):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …
  • BioTime Inc (BTX)-医療機器分野:企業M&A・提携分析
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Baxter International Inc (BAX)-製薬・医療分野:企業M&A・提携分析
    Summary Baxter International Inc (Baxter) is one of the leading providers of renal and hospital products. It undertakes the development, manufacture and marketing of medical products for the treatment of end-stage renal diseases. Its portfolio include a comprehensive range of home, acute and in-cent …
  • Abdullah Al-Othaim Markets Co.:企業の戦略・SWOT・財務情報
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Aeroports de Paris SA:戦略・SWOT・企業財務分析
    Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report Summary Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pitney Bowes Inc (PBI):企業の財務・戦略的SWOT分析
    Pitney Bowes Inc (PBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆